Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland. more
Time Frame | ALT | Sector | S&P500 |
---|---|---|---|
1-Week Return | 6.3% | -2.12% | 0.77% |
1-Month Return | 24.62% | -2.54% | 2.65% |
3-Month Return | 46.94% | -6.28% | 12.3% |
6-Month Return | 35.36% | -1.36% | 13.48% |
1-Year Return | 32.41% | 9.29% | 33.47% |
3-Year Return | -1.73% | 10.05% | 32.22% |
5-Year Return | 384.57% | 43.69% | 92.85% |
10-Year Return | -98.22% | 103.1% | 194.31% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 5.80M | 8.19M | 4.41M | (68.00K) | 426.00K | [{"date":"2019-12-31","value":70.88,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":53.88,"profit":true},{"date":"2022-12-31","value":-0.83,"profit":false},{"date":"2023-12-31","value":5.2,"profit":true}] |
Cost of Revenue | 17.07M | 33.51M | 551.30K | 68.00K | 477.00K | [{"date":"2019-12-31","value":50.93,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":1.65,"profit":true},{"date":"2022-12-31","value":0.2,"profit":true},{"date":"2023-12-31","value":1.42,"profit":true}] |
Gross Profit | (11.26M) | (25.32M) | 3.86M | (136.00K) | (51.00K) | [{"date":"2019-12-31","value":-291.89,"profit":false},{"date":"2020-12-31","value":-656.23,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-3.52,"profit":false},{"date":"2023-12-31","value":-1.32,"profit":false}] |
Gross Margin | (194.16%) | (309.40%) | 87.50% | 200.00% | (11.97%) | [{"date":"2019-12-31","value":-97.08,"profit":false},{"date":"2020-12-31","value":-154.7,"profit":false},{"date":"2021-12-31","value":43.75,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-5.99,"profit":false}] |
Operating Expenses | 26.27M | 62.98M | 89.95M | 87.67M | 96.36M | [{"date":"2019-12-31","value":27.26,"profit":true},{"date":"2020-12-31","value":65.37,"profit":true},{"date":"2021-12-31","value":93.36,"profit":true},{"date":"2022-12-31","value":90.99,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (21.46M) | (54.80M) | (96.91M) | (87.74M) | (95.93M) | [{"date":"2019-12-31","value":-2146493500,"profit":false},{"date":"2020-12-31","value":-5479874100,"profit":false},{"date":"2021-12-31","value":-9691404100,"profit":false},{"date":"2022-12-31","value":-8774000000,"profit":false},{"date":"2023-12-31","value":-9592900000,"profit":false}] |
Total Non-Operating Income/Expense | 1.73M | 650.33K | 20.26K | 5.69M | 14.80M | [{"date":"2019-12-31","value":11.67,"profit":true},{"date":"2020-12-31","value":4.39,"profit":true},{"date":"2021-12-31","value":0.14,"profit":true},{"date":"2022-12-31","value":38.46,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Pre-Tax Income | (20.58M) | (54.46M) | (97.09M) | (84.91M) | (88.45M) | [{"date":"2019-12-31","value":-2057863100,"profit":false},{"date":"2020-12-31","value":-5446150100,"profit":false},{"date":"2021-12-31","value":-9709082400,"profit":false},{"date":"2022-12-31","value":-8491000000,"profit":false},{"date":"2023-12-31","value":-8844700000,"profit":false}] |
Income Taxes | (58.50K) | (5.42M) | (919.51K) | (197.00K) | 309.11K | [{"date":"2019-12-31","value":-18.93,"profit":false},{"date":"2020-12-31","value":-1752.49,"profit":false},{"date":"2021-12-31","value":-297.48,"profit":false},{"date":"2022-12-31","value":-63.73,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] |
Income After Taxes | (20.52M) | (49.04M) | (96.17M) | (84.71M) | (88.76M) | [{"date":"2019-12-31","value":-2052013100,"profit":false},{"date":"2020-12-31","value":-4904447700,"profit":false},{"date":"2021-12-31","value":-9617131100,"profit":false},{"date":"2022-12-31","value":-8471300000,"profit":false},{"date":"2023-12-31","value":-8875610500,"profit":false}] |
Income From Continuous Operations | (20.52M) | (49.04M) | (97.09M) | (84.71M) | (88.45M) | [{"date":"2019-12-31","value":-2052013100,"profit":false},{"date":"2020-12-31","value":-4904447700,"profit":false},{"date":"2021-12-31","value":-9709082400,"profit":false},{"date":"2022-12-31","value":-8471300000,"profit":false},{"date":"2023-12-31","value":-8844700000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (20.52M) | (49.04M) | (96.17M) | (84.71M) | (88.45M) | [{"date":"2019-12-31","value":-2052013100,"profit":false},{"date":"2020-12-31","value":-4904447700,"profit":false},{"date":"2021-12-31","value":-9617131100,"profit":false},{"date":"2022-12-31","value":-8471300000,"profit":false},{"date":"2023-12-31","value":-8844700000,"profit":false}] |
EPS (Diluted) | (1.51) | (1.91) | (2.36) | (1.77) | (1.44) | [{"date":"2019-12-31","value":-151,"profit":false},{"date":"2020-12-31","value":-191,"profit":false},{"date":"2021-12-31","value":-236,"profit":false},{"date":"2022-12-31","value":-177,"profit":false},{"date":"2023-12-31","value":-144,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
ALT | |
---|---|
Cash Ratio | 16.14 |
Current Ratio | 16.87 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
ALT | |
---|---|
ROA (LTM) | -39.56% |
ROE (LTM) | -72.96% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
ALT | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.10 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.90 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
ALT | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 13472.64 |
P/B | 4.69 |
Price/FCF | NM |
EV/R | 9376.51 |
EV/Ebitda | NM |
PEG | NM |
Altimmune Inc (ALT) share price today is $9.11
Yes, Indians can buy shares of Altimmune Inc (ALT) on Vested. To buy Altimmune Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in ALT stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Altimmune Inc (ALT) via the Vested app. You can start investing in Altimmune Inc (ALT) with a minimum investment of $1.
You can invest in shares of Altimmune Inc (ALT) via Vested in three simple steps:
The 52-week high price of Altimmune Inc (ALT) is $14.84. The 52-week low price of Altimmune Inc (ALT) is $4.71.
The price-to-earnings (P/E) ratio of Altimmune Inc (ALT) is
The price-to-book (P/B) ratio of Altimmune Inc (ALT) is 4.69
The dividend yield of Altimmune Inc (ALT) is 0.00%
The market capitalization of Altimmune Inc (ALT) is $700.58M
The stock symbol (or ticker) of Altimmune Inc is ALT